Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Singer

Showing results (511-520 of 649) with videos related to

Pageof 65
Sort By:
Journal of the National Cancer Institute|September 8, 2016
Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation CarriersJoanne Kotsopoulos, Tomasz Huzarski, Jacek Gronwald, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2013
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)G G Steger, R Greil, A Lang, et al.
Breast Cancer Research and Treatment|July 11, 2023
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutationJoanne Kotsopoulos, Jacek Gronwald, Tomasz Huzarski, et al.
JAMA|November 9, 2016
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical TrialTheodoros Foukakis, Gunter von Minckwitz, Nils-Olof Bengtsson, et al.
Cancer Letters|June 1, 2019
Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancerCaroline Kreuzinger, Isabel von der Decken, Andrea Wolf, et al.
Breast Cancer Research and Treatment|January 25, 2014
Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriersJoanne Kotsopoulos, Jan Lubinski, Pal Moller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2021
Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor ResponseQing Zhou, Simon P Gampenrieder, Sophie Frantal, et al.
Cancer|November 29, 2024
The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutationBryson W Katona, Jan Lubinski, Tuya Pal, et al.
Nature Medicine|August 8, 2022
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trialRupert Bartsch, Anna Sophie Berghoff, Julia Furtner, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 27, 2022
Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A ReappraisalJoanne Kotsopoulos, Jan Lubinski, Jacek Gronwald, et al.
Pageof 65

Showing results (511-520 of 649) with videos related to

Sort By:
Pageof 65
Journal of the National Cancer Institute|September 8, 2016
Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation CarriersJoanne Kotsopoulos, Tomasz Huzarski, Jacek Gronwald, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2013
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)G G Steger, R Greil, A Lang, et al.
Breast Cancer Research and Treatment|July 11, 2023
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutationJoanne Kotsopoulos, Jacek Gronwald, Tomasz Huzarski, et al.
JAMA|November 9, 2016
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical TrialTheodoros Foukakis, Gunter von Minckwitz, Nils-Olof Bengtsson, et al.
Cancer Letters|June 1, 2019
Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancerCaroline Kreuzinger, Isabel von der Decken, Andrea Wolf, et al.
Breast Cancer Research and Treatment|January 25, 2014
Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriersJoanne Kotsopoulos, Jan Lubinski, Pal Moller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2021
Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor ResponseQing Zhou, Simon P Gampenrieder, Sophie Frantal, et al.
Cancer|November 29, 2024
The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutationBryson W Katona, Jan Lubinski, Tuya Pal, et al.
Nature Medicine|August 8, 2022
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trialRupert Bartsch, Anna Sophie Berghoff, Julia Furtner, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 27, 2022
Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A ReappraisalJoanne Kotsopoulos, Jan Lubinski, Jacek Gronwald, et al.
Pageof 65